Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck plans to boost its immunotherapy drugs with tumor-bursting viruses

Merck will acquire Viralytics, whose oncolytic virus therapy may help broaden the use of the checkpoint inhibitor therapy Keytruda

by Ryan Cross
February 21, 2018

Article:

This article has been sent to the following recipient: